PASSERI DANIEL R
Known title: CHIEF EXECUTIVE OFFICERCIK: 0001190121
PASSERI DANIEL R's purchase track record
How the stock did after each of PASSERI DANIEL R's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since September 24, 2021
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-42.2%
3 months: -17.9%
Beat the S&P 500
0%
median -41.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/16/2024 | CUE | $31K | -6.9% | -42.2% | -0.7% |
| 8/14/2023 | CUE | $9K | -22.1% | -16.9% | +11.8% |
| 9/24/2021 | CUE | $50K | -17.9% | -65.5% | +2.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CUE | ▲ Buy | Open Market | 30,000 | $31K | 12/16/2024 | View on chart |
| CUE | ▲ Buy | Open Market | 3,000 | $9K | 8/14/2023 | View on chart |
| CUE | ▲ Buy | Option Exercise | 75,000 | — | 3/31/2022 | View on chart |
| CUE | ▼ Sell | Tax Withholding | 32,122 | $157K | 3/31/2022 | View on chart |
| CUE | ▼ Sell | Gift | 10,000 | $0 | 3/31/2022 | View on chart |
| CUE | ▲ Buy | Option Exercise | 75,000 | — | 9/30/2021 | View on chart |
| CUE | ▼ Sell | Tax Withholding | 31,677 | $462K | 9/30/2021 | View on chart |
| CUE | ▲ Buy | Open Market | 3,400 | $50K | 9/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.